Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tiffany Clay-Ramsey

Dermatology Marietta, GA Medical Doctor

NPI 1508152232 CMS profile 1392276

4939 Lower Roswell Rd Ste 104A, Marietta, GA 30068

Open in the dashboard

General payments

$206,621

773 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tiffany Clay-Ramsey of Marietta, GA is reported in the CMS Open Payments database as having received $206,621 across 773 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $35,010 132
2024 General $92,121 189
2023 General $33,016 128
2022 General $30,263 109
2021 General $12,628 54
2020 General $1,136 53
2019 General $2,448 108

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tiffany Clay-Ramsey
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Tiffany Clay-Ramsey were reported at $35,010. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Tiffany Clay-Ramsey Dermatology median Middle half National median
2019 $2,448 $454 $129–$1,240 $163
2020 $1,136 $235 $81–$756 $114
2021 $12,628 $377 $108–$1,108 $132
2022 $30,263 $514 $143–$1,391 $149
2023 $33,016 $607 $159–$1,674 $160
2024 $92,121 $751 $204–$1,903 $164
2025 $35,010 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Biotech, Inc. $153,884 178 payments
  2. Lilly USA, LLC $19,719 58 payments
  3. Janssen Scientific Affairs, LLC $18,367 22 payments
  4. Galderma Laboratories, L.P. $3,723 32 payments
  5. AbbVie, Inc. $2,127 107 payments
  6. Regeneron Healthcare Solutions, Inc. $1,502 61 payments
  7. Pfizer Inc. $1,496 87 payments
  8. Mayne Pharma Inc. $617 35 payments
  9. UCB, Inc. $543 16 payments
  10. Genzyme Corporation $512 15 payments
  11. Other $4,131 162 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $161,732 55 payments
  2. Travel and Lodging $23,022 70 payments
  3. Food and Beverage $17,538 640 payments
  4. Consulting Fee $4,100 3 payments
  5. Education $229 5 payments
Products named General payments · program years 2019–2025
  1. TREMFYA $172,159 194 payments
  2. TALTZ $19,528 52 payments
  3. SIMPONI ARIA $4,254 7 payments
  4. TWYNEO $1,732 5 payments
  5. AKLIEF $1,589 4 payments
  6. DUPIXENT $1,342 55 payments
  7. RINVOQ $1,142 53 payments
  8. EUCRISA $918 58 payments
  9. CIBINQO $775 61 payments
  10. SKYRIZI $614 29 payments
  11. Other $8,046 354 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

264

Median for Dermatology: 534

Drug cost

$53,778

Median for Dermatology: $67,151

Branded share of claims

4.5%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 12 $45,482
Tacrolimus Generic 18 $2,081
Metronidazole Generic 16 $1,202
Fluorouracil Generic 20 $1,123
Clobetasol Propionate Generic 34 $1,100
Betamethasone Dipropionate Generic 21 $788
Ketoconazole Generic 39 $495
Triamcinolone Acetonide Generic 43 $445
Doxycycline Hyclate Generic 18 $393
Fluocinonide Generic 13 $306

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$50,239

Of which drugs: $291

Medicare patients

367

Average age 74

Services billed

1,261

213 women, 154 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 38%
Ischemic heart disease 26%
Diabetes 22%
Chronic kidney disease 20%
Cancer 16%
Depression 14%
Atrial fibrillation 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 11 17 $13

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
$90,076 — —
RINVOQ
$328 — —
SOTYKTU
$215 — —
COSENTYX
$210 — —
DUPIXENT
$207 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

773 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record